

References

I-38

1. Rituxan® (rituximab) package insert, for intravenous use [package insert]. Genentech, Inc., San Francisco, CA. 12/2021.
2. Wang K, Jiang Y, Zheng W, et al. Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in b-cell lymphoma. *PLoS One*. 2013;8(2):e56829.
3. Wang M, Fowler N, Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. 2013;27(9):1902-9.
4. Ohmachi K, Niitsu N, Uchida T, et al. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology*. 2013;31(17):2103-2109.
5. Mok C. Rituximab for the treatment of rheumatoid arthritis: An update. *Drug Design, Development and Therapy*. 2014;8: 87-100.
6. Darwish M, Burke J, Hellriegel E, et al. An evaluation of the potential for drug drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma. *Cancer Chemotherapy and Pharmacology*. 2014;73:1119-1127.
7. Harb D, Moukadem H, Nayfe R, et al. The off-label use of rituximab for the management of inflammatory disorders: American University of Beirut Medical Center experience. *Archive of Rheumatology*. 2014;29(3):194-202.
8. Mealy M, Levy M. Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab. *Journal of Neuroimmunology*. 2015;287:29-30.
9. Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica. *Journal of the Neurological Sciences*. 2015;351(1-2):31-35.
10. Smolen J, Landewe, Breedveld F, et al. European League Against Rheumatism's (EULAR) recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Annals of the Rheumatic Diseases*. 2014;73(3):492-509.
11. Hui-Yuen JS, Nguyen SC, Asknase AD. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. 2016;25:1086-1096.
12. Memon AB, Javed A, Caon C, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. *PLoS ONE*. 2018;13(1): e0190425.
13. MICROMEDEX®SOLUTIONS Compendia. 2024. Rituximab.

14. MICROMEDEX® SOLUTIONS Compendia. 2024. Rituximab/Hyaluronidase Human, Recombinant.
15. Clinical Pharmacology Compendia. 2024. Tampa FL: Gold Standard, Inc. Rituximab and Hyaluronidase.
16. Clinical Pharmacology Compendia. 2024. Tampa FL: Gold Standard, Inc. Rituximab.
17. NCCN Drugs & Biologics Compendium™. Rituximab. 2024. National Comprehensive Cancer Network (NCCN).
18. NCCN Drugs & Biologics Compendium™. Rituximab and hyaluronidase human. 2024. National Comprehensive Cancer Network (NCCN).
19. Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. *Annals of the Rheumatic Diseases*. Published Online First: 17 January 2014.
20. Lorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. *J Neurol*. 2015; 262(5):1115-1119.
21. Harambat J, Lamireau D, Delmas Y, et al. Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review. *Pediatr Crit Care Med*. 2011; 12(2):e90-e93.
22. Coiffier B, Juan-Manuel S, Jurczak W, Kim JS, Nagarkar RV, Zhavrid E, et al. Pharmacokinetic and safety of CT-P10, a biosimilar candidate to the rituximab reference product, in patients with newly diagnosed advanced stage follicular lymphoma (AFL). 2016;22(128):1807.
23. Kim WS, Buske C, Kwak LW, Ogura M, Coiffier B, Lee S, et al. Similar efficacy and safety of CT-P10 and reference rituximab in patients with advanced stage follicular lymphoma: updated phase III study results. Post presented at: The American Society of Hematology Annual Meeting; December 1, 2018; San Diego, CA.
24. Ito k, Okamoto M, Inaguma Y, et al. Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma. 2016;91:302-310.
25. Davies A, Berge C, Boehnke A, et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. *Adv Ther*. 2017;34:2210-2231.
26. Rituxan Hycela® (rituximab and hyaluronidase human) injection for subcutaneous use [package insert]. Genentech, Inc. South San Francisco, CA Revised 06/2021.
27. Ruxience (rituximab-pwr) injection, for intravenous use [package insert]. Pfizer Labs Division of Pfizer Inc. New York, New York. Revised 10/2023.

28. Truxima (rituximab-abbs) injection, for intravenous use [package insert]. Celltrion, Inc. North Wales, PA. Revised 02/2022.
29. National Comprehensive Cancer Network (NCCN). Rituximab-abbs. NCCN Drugs and Biologics Compendium®. 2024.
30. National Comprehensive Cancer Network (NCCN). Rituximab-pvvr. NCCN Drugs and Biologics Compendium®. 2024.
31. MICROMEDEX®SOLUTIONS Compendia. 2024. Rituximab-abbs.
32. MICROMEDEX®SOLUTIONS Compendia. 2024. Rituximab-pvvr.
33. Clinical Pharmacology Compendia. 2024. Tampa FL: Gold Standard, Inc. Rituximab-abbs.
34. Clinical Pharmacology Compendia. 2024. Tampa FL: Gold Standard, Inc. Rituximab-pvr.
35. Riabni (rituximab-arxx) injection, for intravenous use [package insert]. Amgen, Inc. Thousand Oaks, CA. Revised 02/2023.
36. Micromedex®Solutions Compendia. 2024. Rituximab-arxx.
37. National Comprehensive Cancer Network (NCCN). Rituximab-arxx. NCCN Drugs and Biologics Compendium®. 2024.
38. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69(9):1629-35.
39. Rituximab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated June 29, 2016.